+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-01-23Number of Pages: 82

Kidney Cancer Drugs Market (Major Drugs: Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient (Pazopanib)) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Kidney Cancer Drugs Market
2.2 Comparative Analysis: Global Kidney Cancer Drugs Market, By Geography, 2013 and 2020 (Value %)
 
Chapter 3 Global Kidney Cancer Drugs Market Overview
3.1 Market Dynamics and Overview
3.2 Market Drivers
     3.2.1 Rising Incidence of Kidney Cancer Expected to Boost Market Growth
     3.2.2 Increasing Geriatric Population Likely to Fuel the Growth of Kidney Cancer Drugs Market
             3.2.2.1.1 Global Percentage Change in the World’s Population by Age: 2010-2050
     3.2.3 Approval of Novel Molecules is Expected to Drive Market Growth
3.3 Market Restraints
     3.3.1 High Prices of Branded Cancer Drugs might Impede the Growth of the Market
     3.3.2 Increasing Preference for Generic Drug Variants might Negatively Influence the Market Growth
3.4 Market Opportunities
     3.4.1 Focusing on Emerging Markets
3.5 Event Impact Analysis
3.6 Regulatory Framework
3.7 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography
3.8 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2013 (Value %)
 
Chapter 4 Global Kidney Cancer Drugs Market, by Major Branded Drugs
4.1 Overview
     4.1.1 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2012 – 2020 (USD Million)
4.2 Sutent (Sunitinib)
     4.2.1 Global Sutent (Sunitinib) Market Revenue, 2012 – 2020 (USD Million)
4.3 Nexavar (Sorafenib)
     4.3.1 Global Nexavar (Sorafenib) Market Revenue, 2012 – 2020 (USD Million)
4.4 Afinitor (Everolimus)
     4.4.1 Global Afinitor (Everolimus) Market Revenue, 2012 – 2020 (USD Million)
4.5 Votrient (Pazopanib)
     4.5.1 Global Votrient (Pazopanib) Market Revenue, 2012 – 2020 (USD Million)
4.6 Inlyta (Axitinib)
     4.6.1 Global Inlyta (Axitinib) Market Revenue, 2012 – 2020 (USD Million)
4.7 Avastin (Bevacizumab)
     4.7.1 Global Avastin (Bevacizumab) Market Revenue, 2012 – 2020 (USD Million)
4.8 Torisel (Temsirolimus)
     4.8.1 Global Torisel (Temsirolimus) Market Revenue, 2012 – 2020 (USD Million)
4.9 Proleukin (Aldesleukin)
     4.9.1 Global Proleukin (Aldesleukin) Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 5 Global Kidney Cancer Drugs Market, Pipeline Analysis
5.1 Overview
     5.1.1 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 – 2020 (USD Million)
5.2 Opdivo (Nivolumab) (Bristol-Myers Squibb)
     5.2.1 Global Opdivo Market Revenue, 2015 – 2020 (USD Million)
5.3 Keytruda (Anti PD 1) (Pembrolizumab) (Merck & Co., Inc.)
     5.3.1 Global Keytruda Market Revenue, 2015 – 2020 (USD Million)
5.4 Cabozantinib (XL184) (Exelixis, Inc.)
     5.4.1 Global Cabozantinib Market Revenue, 2017 – 2020 (USD Million)
5.5 AGS-003 (Argus Therapeutics, Inc.)
     5.5.1 Global AGS-003 Market Revenue, 2017 – 2020 (USD Million)
5.6 Dovitinib (TK1258) [Novartis AG]
     5.6.1 Global Dovitinib Market Revenue, 2018 – 2020 (USD Million)
 
Chapter 6 Global Kidney Cancer Drugs Market, by Geography
6.1 Overview
     6.1.1 Global Kidney Cancer Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)
6.2 North America
     6.2.1 North America Kidney Cancer Drugs Market Revenue, 2012–2020 (USD Million)
6.3 Europe
     6.3.1 Europe Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
6.4 Asia Pacific
     6.4.1 Asia Pacific Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
6.5 Rest of the World (RoW)
     6.5.1 Rest of the World Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
 
Chapter 7 Recommendations
 
Chapter 8 Company Profiles
8.1 Bayer AG
     8.1.1 Company Overview
     8.1.2 Financial Overview
     8.1.3 Product Portfolio
     8.1.4 Business Strategy
     8.1.5 Recent Developments
8.2 F. Hoffmann-La Roche, Ltd.
     8.2.1 Company Overview
     8.2.2 Financial Overview
     8.2.3 Product Portfolio
     8.2.4 Business Strategy
     8.2.5 Recent Developments
8.3 GlaxoSmithKline, plc
     8.3.1 Company Overview
     8.3.2 Financial Overview
     8.3.3 Product Portfolio
     8.3.4 Business Strategy
     8.3.5 Recent Developments
8.4 Novartis AG
     8.4.1 Company Overview
     8.4.2 Financial Overview
     8.4.3 Product Portfolio
     8.4.4 Business Strategy
     8.4.5 Recent Developments
8.5 Pfizer, Inc.
     8.5.1 Company Overview
     8.5.2 Financial Overview
     8.5.3 Product Portfolio
     8.5.4 Business Strategy
     8.5.5 Recent Developments

List of Figures
 
FIG. 1 Kidney Cancer Drugs: Market Segmentation
FIG. 2 Global Kidney Cancer Drugs Market, by Major Branded Drugs, 2013 (USD Million)
FIG. 3 Global Kidney Cancer Pipeline Drugs Market (USD Million)
FIG. 4 Comparative Analysis: Global Kidney Cancer Drugs Market, by Geography, 2013 and 2020 (Value %)
FIG. 5 Kidney Cancer Drugs Market, Drivers and Restraints
FIG. 6 Global Percentage Change in the World’s Population by Age: 2010 - 2050
FIG. 7 Major Developments in Kidney Cancer Drugs Market
FIG. 8 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography
FIG. 9 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2013 (Value %)
FIG. 10 Global Sutent (Sunitinib) Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 Global Nexavar (Sorafenib) Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 Global Afinitor (Everolimus) Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 Global Votrient (Pazopanib) Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Global Inlyta (Axitinib) Market Revenue, 2012 – 2020 (USD Million)
FIG. 15 Global Avastin (Bevacizumab) Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Global Torisel (Temsirolimus) Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 Global Proleukin (Aldesleukin) Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 Global Opdivo Market Revenue, 2015 – 2020 (USD Million)
FIG. 19 Global Keytruda Market Revenue, 2015 – 2020 (USD Million)
FIG. 20 Global Cabozantinib Market Revenue, 2017 – 2020 (USD Million)
FIG. 21 Global AGS-003 Market Revenue, 2017 – 2020 (USD Million)
FIG. 22 Global Dovitinib Market Revenue, 2018 – 2020 (USD Million)
FIG. 23 North America Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
FIG. 24 Europe Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
FIG. 25 Asia Pacific Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
FIG. 26 Rest of the World Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
FIG. 27 Bayer AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 28 F. Hoffmann-La Roche, Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 29 GlaxoSmithKline, plc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 30 Annual Revenue: Novartis AG 2011 – 2013 (USD Million)
FIG. 31 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables
 
TABLE 1 Market Snapshot: Global Kidney Cancer Market
TABLE 2 Stages of RCC, According to the U.S. TNM Classification
TABLE 3 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2012 – 2020 (USD Million)
TABLE 4 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 – 2020 (USD Million)
TABLE 5 Global Kidney Cancer Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)


 
 
Back To Top